Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome

Blood

Volumn 98, Issue 3, 2001, Pages 573-578

  Garrett Nichols, W ^a   Corey, Lawrence ^a   Gooley, Ted ^a   Davis, Chris ^a   Boeckh, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; ARTIFICIAL VENTILATION; AUTOTRANSPLANTATION; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NASOPHARYNX; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS PNEUMONIA; VIRUS SHEDDING;

EID: 0035437136     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.573     Document Type: Article

References (14)

1. Marx A, Gary HE Jr, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis. 1999;29:134-140.
2. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996;23:1033-1037.
3. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992;326:921-926.
4. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
5. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89:3880-3887.
6. Quabeck K. The lung as a critical organ in marrow transplantation. Bone Marrow Transplant. 1994;14:S19-S28.
7. Elizaga J, Olavarria E, Apperley JF, Goldman JM, Ward KN. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis. 2001;32:413-418.
8. Fiore AE, Iverson C, Messmer T, et al. Outbreak of pneumonia in a long-term care facility: antecedent human parainfluenza virus 1 infection may predispose to bacterial pneumonia. J Am Geriatr Soc. 1998;46:1112-1117.
9. Slag S, Muro-Cacho C, Robertson S, Huang Y, Kaplan D. Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3. Proc Natl Acad Sci U S A. 1994;91:6293-6297.
10. Sieg S, King C, Huang Y, Kaplan D. The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. J Virol. 1996;70:4845-4848.
11. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986;30:201.
12. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoietic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis. 2000;31:1516-1518.
13. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19:905-908.
14. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, ed. Fields Virology. Philadelphia, PA: Lippincott-Raven; 1996:1205-1210.